1-20 of 23
Peter Ordentlich
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 4027: From tumor progression to therapeutic control: Combinatorial targeting of immune vulnerabilities in TNBC

Amanda Poissonnier, Eivind Valen Egeland, Wesley Horton, Shamilene Sivagnanam, Orian Stapleton, Rossin Erbe, Nell Kirchberger, Konjit Betre, Alyza Skaist, Ludmila Danilova, Andrew Fields, Peter Ordentlich, Andrew C. Adey, Elana J. Fertig, Lisa M. Coussens
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 4027.
https://doi.org/10.1158/1538-7445.AM2024-4027
Published: 22 March 2024
View article titled, Abstract 4027: From tumor progression to therapeutic control: Combinatorial targeting of immune vulnerabilities in TNBC
Journal Articles

Abstract 4164: Relieving immune suppressive pathways in breast cancer to improve outcomes

Amanda Poissonnier, Eivind Valen Egeland, Rossin Erbe, Wesley Horton, Ana Howells-Ferreira, Shamilene Sivagnanam, Nell Kirchberger, Dhaarini Murugan, Andrew Fields, Peter Ordentlich, Andrew C. Adey, Elana J. Fertig, Lisa M. Coussens
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 4164.
https://doi.org/10.1158/1538-7445.AM2023-4164
Published: 04 April 2023
View article titled, Abstract 4164: Relieving immune suppressive pathways in breast cancer to improve outcomes
Journal Articles

Abstract LB566: Class 1 HDAC inhibition induces antitumor immunity by NF-kB-mediated enhanced metabolic fitness and generation of unique effector function enriched memory CD8 T cell subtype

Nour Shobaki, Pankaj Gaur, Rahul Nadre, Vivek Verma, Peter Ordentlich, Lei Wang, Nazli Jafarzadeh, Wael Traboulsi, Mikayel Mkrtichyan, Seema Gupta, Samir N. Khleif
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): LB566.
https://doi.org/10.1158/1538-7445.AM2022-LB566
Published: 15 June 2022
View article titled, Abstract LB566: Class 1 HDAC inhibition induces antitumor immunity by NF-kB-mediated enhanced metabolic fitness and generation of unique effector function enriched memory CD8 T cell subtype
Journal Articles

Abstract CT242: SNDX-6352-0502: A phase 1, open-label, dose escalation trial to investigate the safety, tolerability, pharmacokinetics and pharmacodynamic activity of SNDX-6352 in combination with durvalumab in patients with unresectable, recurrent, locally-advanced, or metastatic solid tumors

Anthony W. Tolcher, Drew Rasco, Sunil Sharma, Matthew Taylor, Christine Quaranto, David L. Tamang, Robert Nordness, Michael L. Meyers, Serap Sankoh, Peter Ordentlich, Nilo Azad
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): CT242.
https://doi.org/10.1158/1538-7445.AM2020-CT242
Published: 15 August 2020
View article titled, Abstract CT242: SNDX-6352-0502: A phase 1, open-label, dose escalation trial to investigate the safety, tolerability, pharmacokinetics and pharmacodynamic activity of SNDX-6352 in combination with durvalumab in patients with unresectable, recurrent, locally-advanced, or metastatic solid tumors
Journal Articles

Abstract CT149: SNDX-6352-0502 - A phase 1, open-label, dose escalation trial to investigate the safety, tolerability, pharmacokinetics and pharmacodynamic activity of SNDX-6352 monotherapy in patients with unresectable, recurrent, locally-advanced, or metastatic solid tumors

Nilo Azad, Drew Rasco, Sunil Sharma, Matthew Taylor, Christine Quaranto, David L. Tamang, Robert Nordness, Michael L. Meyers, Serap Sankoh, Peter Ordentlich, Anthony W. Tolcher
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): CT149.
https://doi.org/10.1158/1538-7445.AM2020-CT149
Published: 15 August 2020
View article titled, Abstract CT149: SNDX-6352-0502 - A phase 1, open-label, dose escalation trial to investigate the safety, tolerability, pharmacokinetics and pharmacodynamic activity of SNDX-6352 monotherapy in patients with unresectable, recurrent, locally-advanced, or metastatic solid tumors
Journal Articles

Abstract CT041: Identification of gene signatures associated with response in a Phase II trial of entinostat (ENT) plus pembrolizumab (PEMBRO) in non-small cell lung cancer (NSCLC) patients whose disease has progressed on or after anti-PD-(L)1 therapy

Peter Ordentlich, Lei Wang, David Tamang, Amy H. Sullivan, Sally E. Church, Dan Rozelle, Michael L. Meyers, Suresh S. Ramalingam, Matthew D. Hellmann
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): CT041.
https://doi.org/10.1158/1538-7445.AM2019-CT041
Published: 01 July 2019
View article titled, Abstract CT041: Identification of gene signatures associated with response in a Phase II trial of entinostat (ENT) plus pembrolizumab (PEMBRO) in non-small cell lung cancer (NSCLC) patients whose disease has progressed on or after anti-PD-(L)1 therapy
Journal Articles

Abstract CT072: Efficacy and safety of entinostat (ENT) and pembrolizumab (PEMBRO) in patients with melanoma previously treated with anti-PD1 therapy

Ryan J. Sullivan, Stergios J. Moschos, Melissa L. Johnson, Mateusz Opyrchal, Peter Ordentlich, Susan Brouwer, Serap Sankoh, Michael L. Meyers, Sanjiv S. Agarwala
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): CT072.
https://doi.org/10.1158/1538-7445.AM2019-CT072
Published: 01 July 2019
View article titled, Abstract CT072: Efficacy and safety of entinostat (ENT) and pembrolizumab (PEMBRO) in patients with melanoma previously treated with anti-PD1 therapy
Journal Articles

Abstract 123: Enhanced anti-tumor activity of the combination of entinostat and NKTR214 in renal and colon cancer tumor models

Lei Wang, Fei Chen, Tingting Li, Peter Ordentlich, Jonathan Zalevsky
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 123.
https://doi.org/10.1158/1538-7445.AM2018-123
Published: 01 July 2018
View article titled, Abstract 123: Enhanced anti-tumor activity of the combination of entinostat and NKTR214 in renal and colon cancer tumor models
Journal Articles

Abstract 1740: Epigenetic reprogramming of the tumor microenvironment by entinostat increases tumor sensitivity to multivalent immunotherapy combinations with an IL-15 superagonist plus vaccine or immune checkpoint blockade

Kristin C. Hicks, Karin M. Knudson, Frank R. Jones, Peter Ordentlich, Shahrooz Rabizadeh, Hing C. Wong, James W. Hodge, Jeffrey Schlom, Sofia R. Gameiro
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 1740.
https://doi.org/10.1158/1538-7445.AM2018-1740
Published: 01 July 2018
View article titled, Abstract 1740: Epigenetic reprogramming of the tumor microenvironment by entinostat increases tumor sensitivity to multivalent immunotherapy combinations with an IL-15 superagonist plus vaccine or immune checkpoint blockade
Journal Articles

Abstract 2146: Activity of entinostat alone and in combination with cisplatin in a panel of low passage adenoid cystic carcinoma patient-derived xenograft (PDX) models

Amanda Mangold, Melissa Rundle, Nicole Spardy Burr, Alyssa Moriarty, Priscila Goncalves, Rogerio Castilho, Peter Ordentlich, Jeffrey Kaufman, Kyriakos Papadopoulos, Michael J. Wick
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 2146.
https://doi.org/10.1158/1538-7445.AM2018-2146
Published: 01 July 2018
View article titled, Abstract 2146: Activity of entinostat alone and in combination with cisplatin in a panel of low passage adenoid cystic carcinoma patient-derived xenograft (PDX) models
Journal Articles

Abstract CT179: Safety, efficacy, and immune correlates of alternative doses and schedules of entinostat combined with pembrolizumab in patients with advanced solid tumors - results from SNDX-275-0141 phase I trial

Anthony W. Tolcher, Michael L. Meyers, Dmitry Gabrilovich, Fang Wang, Jane Trepel, Min-Jung Lee, Emmett Schmitt, Christine Quaranto, Serap Sankoh, David Tamang, Peter Ordentlich
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): CT179.
https://doi.org/10.1158/1538-7445.AM2018-CT179
Published: 01 July 2018
View article titled, Abstract CT179: Safety, efficacy, and immune correlates of alternative doses and schedules of entinostat combined with pembrolizumab in patients with advanced solid tumors - results from SNDX-275-0141 phase I trial
Journal Articles

Abstract 3761: Histone deacetylase inhibitor, Entinostat enhances the tumor specific immune response by generating T-cell central memory in the TME

Pankaj Gaur, Vivek Verma, Rahul Nandre, Pooja Vir, Hua Wang, Baolin Kang, Peter Ordentlich, Lei Wang, Seema Gupta, Samir N. Khleif
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 3761.
https://doi.org/10.1158/1538-7445.AM2018-3761
Published: 01 July 2018
View article titled, Abstract 3761: Histone deacetylase inhibitor, Entinostat enhances the tumor specific immune response by generating T-cell central memory in the TME
Journal Articles

Abstract 5595: HDAC inhibitor Entinostat disrupts function of PMN-MDSC

Ayumi Hashimoto, Vinit Kumar, Peter Ordentlich, Dmitry I. Gabrilovich
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): 5595.
https://doi.org/10.1158/1538-7445.AM2017-5595
Published: 01 July 2017
View article titled, Abstract 5595: HDAC inhibitor Entinostat disrupts function of PMN-MDSC
Journal Articles

Combined Treatment with Epigenetic, Differentiating, and Chemotherapeutic Agents Cooperatively Targets Tumor-Initiating Cells in Triple-Negative Breast Cancer

Vanessa F. Merino, Nguyen Nguyen, Kideok Jin, Helen Sadik, Soonweng Cho, Preethi Korangath, Liangfeng Han, Yolanda M.N. Foster, Xian C. Zhou, Zhe Zhang, Roisin M. Connolly, Vered Stearns, Syed Z. Ali, Christina Adams, Qian Chen, Duojia Pan, David L. Huso, Peter Ordentlich, Angela Brodie, Saraswati Sukumar
Journal: Cancer Research
Cancer Res (2016) 76 (7): 2013–2024.
https://doi.org/10.1158/0008-5472.CAN-15-1619
Published: 31 March 2016
View article titled, Combined Treatment with Epigenetic, Differentiating, and Chemotherapeutic Agents Cooperatively Targets Tumor-Initiating Cells in Triple-Negative Breast Cancer
Open the PDF for Combined Treatment with Epigenetic, Differentiating, and Chemotherapeutic Agents Cooperatively Targets Tumor-Initiating Cells in Triple-Negative Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract OT2-1-03: A pilot and phase II study of entinostat and anastrozole/tamoxifen in women with triple negative breast cancer (TNBC) to evaluate biomarkers and surrogates for response

Saranya Chumsri, Gauri Sabnis, Nancy Tait, Jane Lewis, Emily Bellavance, Susan Kesmodel, Steven Feigenberg, Katherine RH Tkaczuk, Peter Ordentlich, Martin J Edelman, Angela H Brodie
Journal: Cancer Research
Cancer Res (2015) 75 (9_Supplement): OT2-1-03.
https://doi.org/10.1158/1538-7445.SABCS14-OT2-1-03
Published: 01 May 2015
View article titled, Abstract OT2-1-03: A pilot and phase II study of entinostat and anastrozole/tamoxifen in women with triple negative breast cancer (TNBC) to evaluate biomarkers and surrogates for response
Journal Articles

Abstract P6-14-01: A class I histone deacetylase inhibitor, entinostat, enhances lapatinib efficacy in both HER2-overexpressing inflammatory and non-inflammatory breast cancer cells through FOXO3-mediated Bim1 expression

Jangsoon Lee, Chandra Bartholomeusz, Gabriel N Hortobagyi, Peter Ordentlich, Naoto T Ueno
Journal: Cancer Research
Cancer Res (2015) 75 (9_Supplement): P6-14-01.
https://doi.org/10.1158/1538-7445.SABCS14-P6-14-01
Published: 01 May 2015
View article titled, Abstract P6-14-01: A class I histone deacetylase inhibitor, entinostat, enhances lapatinib efficacy in both HER2-overexpressing inflammatory and non-inflammatory breast cancer cells through FOXO3-mediated Bim1 expression
Journal Articles

Abstract 5439: Characterization of the class 1 histone deacetylase inhibitor entinostat in EGFRi acquired resistance models and in combination with cetuximab in NSCLC

Daniel C. Chan, Samir E. Witta, Di Zheng, Veronika Franekova, Xiaomei Sui, Peter Ordentlich, Paul A. Bunn, Fred R. Hirsch
Journal: Cancer Research
Cancer Res (2010) 70 (8_Supplement): 5439.
https://doi.org/10.1158/1538-7445.AM10-5439
Published: 15 April 2010
View article titled, Abstract 5439: Characterization of the class 1 histone deacetylase inhibitor entinostat in EGFRi acquired resistance models and in combination with cetuximab in NSCLC
Journal Articles

Abstract 5593: A combination of HDAC inhibitor Entinostat (MS-275), All Trans Retinoic Acid (ATRA) and low dose Doxorubicin causes regression of established xenografts of triple negative breast cancer

Nguyen K. Nguyen, Preethi Korangath, Gauri Sabnis, Angela Brodie, Peter Ordentlich, Vered Stearns, Saraswati Sukumar
Journal: Cancer Research
Cancer Res (2010) 70 (8_Supplement): 5593.
https://doi.org/10.1158/1538-7445.AM10-5593
Published: 15 April 2010
View article titled, Abstract 5593: A combination of HDAC inhibitor Entinostat (MS-275), All Trans Retinoic Acid (ATRA) and low dose Doxorubicin causes regression of established xenografts of triple negative breast cancer
Journal Articles

HDAC Inhibitor SNDX-275 Induces Apoptosis in erbB2-Overexpressing Breast Cancer Cells via Down-regulation of erbB3 Expression

Xiaoping Huang, Lizhi Gao, Shuiliang Wang, Choon-Kee Lee, Peter Ordentlich, Bolin Liu
Journal: Cancer Research
Cancer Res (2009) 69 (21): 8403–8411.
https://doi.org/10.1158/0008-5472.CAN-09-2146
Published: 28 October 2009
View article titled, HDAC Inhibitor SNDX-275 Induces Apoptosis in erbB2-Overexpressing Breast Cancer Cells via Down-regulation of erbB3 Expression
Open the PDF for HDAC Inhibitor SNDX-275 Induces Apoptosis in erbB2-Overexpressing Breast Cancer Cells via Down-regulation of erbB3 Expression in another window
Journal Articles

Abstract #4547: HDAC inhibitor SNDX-275 induces apoptosis in erbB2-overexpressing breast cancer cells via downregulation of both erbB3 and erbB2 expression

Xiaoping Huang, Lizhi Gao, Shuiliang Wang, Choon-Kee Lee, Peter Ordentlich, Bolin Liu
Journal: Cancer Research
Cancer Res (2009) 69 (9_Supplement): 4547.
Published: 01 May 2009
View article titled, Abstract #4547: HDAC inhibitor SNDX-275 induces apoptosis in erbB2-overexpressing breast cancer cells <em>via</em> downregulation of both erbB3 and erbB2 expression